• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

[Ribociclib in combination with endocrine therapy improves overall survival of pre-/perimenopausal breast cancer patients].

作者信息

Krug David, Fabian Alexander, Dunst Jürgen

机构信息

Klinik für Strahlentherapie, Universitätsklinikum Schleswig-Holstein, Arnold-Heller-Str. 3, 24105, Kiel, Deutschland.

出版信息

Strahlenther Onkol. 2020 Mar;196(3):286-288. doi: 10.1007/s00066-019-01574-y.

DOI:10.1007/s00066-019-01574-y
PMID:31950201
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8012308/
Abstract
摘要

相似文献

1
[Ribociclib in combination with endocrine therapy improves overall survival of pre-/perimenopausal breast cancer patients].瑞博西尼联合内分泌治疗可提高绝经前/围绝经期乳腺癌患者的总生存期
Strahlenther Onkol. 2020 Mar;196(3):286-288. doi: 10.1007/s00066-019-01574-y.
2
Overall Survival with Ribociclib plus Endocrine Therapy in Breast Cancer.瑞博西利联合内分泌治疗乳腺癌的总生存。
N Engl J Med. 2019 Jul 25;381(4):307-316. doi: 10.1056/NEJMoa1903765. Epub 2019 Jun 4.
3
Ribociclib in HR+/HER2- Advanced or Metastatic Breast Cancer Patients.来曲唑联合或不联合瑞博西利治疗激素受体阳性、人表皮生长因子受体 2 阴性晚期或转移性乳腺癌患者的随机、开放性、III 期研究 （仅供参考，实际译文以最终确认为准）
Ann Pharmacother. 2019 May;53(5):501-509. doi: 10.1177/1060028018817904. Epub 2018 Dec 7.
4
Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial.来曲唑联合内分泌治疗激素受体阳性、晚期乳腺癌的绝经前妇女（MONALEESA-7）：一项随机 3 期临床试验。
Lancet Oncol. 2018 Jul;19(7):904-915. doi: 10.1016/S1470-2045(18)30292-4. Epub 2018 May 24.
5
Ribociclib for the treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer.来曲唑与阿那曲唑治疗绝经后激素受体阳性、人表皮生长因子受体 2 阴性晚期乳腺癌的疗效和安全性的 Meta 分析
Expert Rev Anticancer Ther. 2018 Mar;18(3):201-213. doi: 10.1080/14737140.2018.1435275. Epub 2018 Feb 19.
6
MONALEESA clinical program: a review of ribociclib use in different clinical settings.MONALEESA 临床项目：在不同临床环境下使用瑞博西利的综述。
Future Oncol. 2019 Aug;15(23):2673-2686. doi: 10.2217/fon-2019-0130. Epub 2019 Jul 15.
7
Ribociclib and Endocrine Therapy in Breast Cancer. Reply.瑞博西尼与乳腺癌内分泌治疗。回复
N Engl J Med. 2019 Oct 17;381(16):1592-1593. doi: 10.1056/NEJMc1911188.
8
Ribociclib and Endocrine Therapy in Breast Cancer.瑞博西尼与乳腺癌内分泌治疗
N Engl J Med. 2019 Oct 17;381(16):1592. doi: 10.1056/NEJMc1911188.
9
Ribociclib plus letrozole and concomitant palliative radiotherapy for metastatic breast cancer.来曲唑联合瑞波西利及姑息性放疗治疗转移性乳腺癌。
Breast. 2018 Dec;42:1-2. doi: 10.1016/j.breast.2018.08.096. Epub 2018 Aug 9.
10
Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer.瑞博西尼作为激素受体阳性晚期乳腺癌的一线治疗方案
N Engl J Med. 2016 Nov 3;375(18):1738-1748. doi: 10.1056/NEJMoa1609709. Epub 2016 Oct 7.

本文引用的文献

1
AGO Recommendations for the Diagnosis and Treatment of Patients with Locally Advanced and Metastatic Breast Cancer: Update 2019.AGO关于局部晚期和转移性乳腺癌患者诊断与治疗的建议：2019年更新版
Breast Care (Basel). 2019 Aug;14(4):247-255. doi: 10.1159/000500999. Epub 2019 Jul 30.
2
CDK 4/6 inhibitors and stereotactic radiation in the management of hormone receptor positive breast cancer brain metastases.CDK4/6 抑制剂联合立体定向放疗治疗激素受体阳性乳腺癌脑转移
J Neurooncol. 2019 Sep;144(3):583-589. doi: 10.1007/s11060-019-03260-6. Epub 2019 Aug 9.
3
Safety and Efficacy of Palbociclib and Radiation Therapy in Patients With Metastatic Breast Cancer: Initial Results of a Novel Combination.帕博西尼与放射治疗联合用于转移性乳腺癌患者的安全性和有效性：一种新型联合治疗的初步结果
Adv Radiat Oncol. 2019 Apr 3;4(3):453-457. doi: 10.1016/j.adro.2019.03.011. eCollection 2019 Jul-Sep.
4
Alpelisib for -Mutated, Hormone Receptor-Positive Advanced Breast Cancer.阿培利司治疗 - 突变型、激素受体阳性晚期乳腺癌。
N Engl J Med. 2019 May 16;380(20):1929-1940. doi: 10.1056/NEJMoa1813904.
5
Overall Survival with Fulvestrant plus Anastrozole in Metastatic Breast Cancer.氟维司群联合阿那曲唑治疗转移性乳腺癌的总生存期。
N Engl J Med. 2019 Mar 28;380(13):1226-1234. doi: 10.1056/NEJMoa1811714.
6
Severe acute radiation-induced enterocolitis after combined palbociclib and palliative radiotherapy treatment.哌柏西利与姑息性放疗联合治疗后发生的严重急性放射性小肠结肠炎。
Radiother Oncol. 2019 Feb;131:240-241. doi: 10.1016/j.radonc.2018.09.020. Epub 2018 Oct 15.
7
Ribociclib plus letrozole and concomitant palliative radiotherapy for metastatic breast cancer.来曲唑联合瑞波西利及姑息性放疗治疗转移性乳腺癌。
Breast. 2018 Dec;42:1-2. doi: 10.1016/j.breast.2018.08.096. Epub 2018 Aug 9.
8
Preliminary results of the association of Palbociclib and radiotherapy in metastatic breast cancer patients.帕博西尼与放疗联合用于转移性乳腺癌患者的初步结果。
Radiother Oncol. 2018 Jan;126(1):181. doi: 10.1016/j.radonc.2017.09.010. Epub 2017 Sep 27.
9
Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation.奥拉帕利治疗携种系 BRCA 突变的转移性乳腺癌患者。
N Engl J Med. 2017 Aug 10;377(6):523-533. doi: 10.1056/NEJMoa1706450. Epub 2017 Jun 4.
10
Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial.氟维司群联合帕博西尼对比氟维司群联合安慰剂治疗既往内分泌治疗进展的激素受体阳性、HER2 阴性转移性乳腺癌（PALOMA-3）：多中心、双盲、III 期随机对照临床试验的最终分析。
Lancet Oncol. 2016 Apr;17(4):425-439. doi: 10.1016/S1470-2045(15)00613-0. Epub 2016 Mar 3.